Platelet-VWF Complexes Are Preferred Substrates of ADAMTS13 Under Fluid Shear Stress

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Sep 29

PMID 17901248

Citations 69

Authors

Kyuhwan Shim

Patricia J Anderson

Elodee A Tuley

Erin Wiswall

J Evan Sadler

Affiliations

Soon will be listed here.

Abstract

Endothelial cells secrete prothrombotic ultralarge von Willebrand factor (VWF) multimers, and the metalloprotease ADAMTS13 cleaves them into smaller, less dangerous multimers. This reaction is stimulated by tensile force applied to the VWF substrate, which may occur on cell surfaces or in the circulating blood. The cleavage of soluble VWF by ADAMTS13 was accelerated dramatically by a combination of platelets and fluid shear stress applied in a cone-plate viscometer. Platelet-dependent cleavage of VWF was blocked by an anti-GPIbalpha monoclonal antibody or by a recombinant soluble fragment of GPIbalpha that prevents platelet-VWF binding. Multimeric gel analysis showed that shear and platelet-dependent cleavage consumed large VWF multimers. Therefore, ADAMTS13 preferentially acts on platelet-VWF complexes under fluid shear stress. This reaction is likely to account for a majority of VWF proteolysis after secretion and to determine the steady-state size distribution of circulating VWF multimers in vivo.

Citing Articles

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.

Madarati H, DeYoung V, Singh K, Sparring T, Kwong A, Fredenburgh J Sci Rep. 2024; 14(1):9073.

PMID: 38643218 PMC: 11032339. DOI: 10.1038/s41598-024-59672-6.

Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device.

Galeone A, Buccoliero C, Barile B, Nicchia G, Onorati F, Luciani G Int J Mol Sci. 2024; 25(1).

PMID: 38203459 PMC: 10779015. DOI: 10.3390/ijms25010288.

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease.

Ay C, Pabinger I, Kovacevic K, Gelbenegger G, Schorgenhofer C, Quehenberger P Blood Adv. 2022; 6(18):5467-5476.

PMID: 35772170 PMC: 9631691. DOI: 10.1182/bloodadvances.2022007805.

Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.

Risser F, Urosev I, Lopez-Morales J, Sun Y, Nash M Biophys Rev. 2022; 14(2):427-461.

PMID: 35399372 PMC: 8984085. DOI: 10.1007/s12551-022-00950-w.

Device-Induced Hemostatic Disorders in Mechanically Assisted Circulation.

Wang S, Griffith B, Wu Z Clin Appl Thromb Hemost. 2021; 27:1076029620982374.

PMID: 33571008 PMC: 7883139. DOI: 10.1177/1076029620982374.

References

Chauhan A, Motto D, Lamb C, Bergmeier W, Dockal M, Plaimauer B . Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006; 203(3):767-76. PMC: 2118248. DOI: 10.1084/jem.20051732. View

Wang Q, Shorten D, Xu X, Shaw G, Schaub R, Shea C . Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. Pharm Res. 2006; 23(8):1743-9. DOI: 10.1007/s11095-006-9018-1. View

Raines G, Aumann H, Sykes S, Street A . Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res. 1990; 60(3):201-12. DOI: 10.1016/0049-3848(90)90181-b. View

Budde U, Dent J, Berkowitz S, Ruggeri Z, ZIMMERMAN T . Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986; 68(6):1213-7. View

Feys H, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N . ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006; 4(5):955-62. DOI: 10.1111/j.1538-7836.2006.01833.x. View

Baenziger N, MAJERUS P . Isolation of human platelets and platelet surface membranes. Methods Enzymol. 1974; 31:149-55. DOI: 10.1016/0076-6879(74)31015-4. View

Sutherland J, OBrien L, Lillicrap D, Weaver D . Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model. 2004; 10(4):259-70. DOI: 10.1007/s00894-004-0194-9. View

Goto S, Kasahara H, Sakai H, Goto M, Ono M, Ikeda Y . Functional compensation of the low platelet count by increased individual platelet size in a patient with May-Hegglin anomaly presenting with acute myocardial infarction. Int J Cardiol. 1998; 64(2):171-7. DOI: 10.1016/s0167-5273(98)00043-6. View

Sadler J . Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67:395-424. DOI: 10.1146/annurev.biochem.67.1.395. View

10.

Anderson P, Kokame K, Sadler J . Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem. 2005; 281(2):850-7. DOI: 10.1074/jbc.M504540200. View

11.

Tsai H . Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996; 87(10):4235-44. View

12.

Zheng X, Chung D, Takayama T, Majerus E, Sadler J, Fujikawa K . Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276(44):41059-63. DOI: 10.1074/jbc.C100515200. View

13.

Dent J, Berkowitz S, Ware J, Kasper C, Ruggeri Z . Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990; 87(16):6306-10. PMC: 54522. DOI: 10.1073/pnas.87.16.6306. View

14.

Tsai H, Lian E . Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-94. PMC: 3159001. DOI: 10.1056/NEJM199811263392203. View

15.

Cruz M, Handin R, Wise R . The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J Biol Chem. 1993; 268(28):21238-45. View

16.

Miura S, Li C, Cao Z, Wang H, Wardell M, Sadler J . Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem. 2000; 275(11):7539-46. DOI: 10.1074/jbc.275.11.7539. View

17.

Sugimoto M, Dent J, McCLINTOCK R, Ware J, Ruggeri Z . Analysis of structure-function relationships in the platelet membrane glycoprotein Ib-binding domain of von Willebrand's factor by expression of deletion mutants. J Biol Chem. 1993; 268(16):12185-92. View

18.

Miller J, Cunningham D, Lyle V, Finch C . Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A. 1991; 88(11):4761-5. PMC: 51746. DOI: 10.1073/pnas.88.11.4761. View

19.

Shankaran H, Neelamegham S . Hydrodynamic forces applied on intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J. 2003; 86(1 Pt 1):576-88. PMC: 1303826. DOI: 10.1016/S0006-3495(04)74136-3. View

20.

Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F . Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003; 349(4):343-9. DOI: 10.1056/NEJMoa022831. View